COMPANIES COVERED
Eli LillyDownload FREE Report Sample
Download Free sampleAttention Deficit/Hyperactivity Disorder (ADHD) is a psychiatric disorder with an estimated global prevalence of 5.3% in children and adolescents. Diagnosis most commonly occurs in children, but the importance of identifying ADHD in the adult population has risen in the past decade. However, diagnosis remains difficult due to unknown genetic causes and a lack of accurate biomarkers.
ADHD Therapeutics Market contains market size and forecasts of ADHD Therapeutics in Global, including the following market information:
Global ADHD Therapeutics Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global ADHD Therapeutics market was valued at 17940 million in 2021 and is projected to reach US$ 23180 million by 2028, at a CAGR of 3.7% during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Stimulants Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of ADHD Therapeutics include Eli Lilly, Novartis, Takeda, Pfizer, GlaxoSmithKline, Mallinckrodt Pharmaceuticals, Hisamitsu Pharmaceutical, Impax Laboratories and Johnson & Johnson, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the ADHD Therapeutics companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global ADHD Therapeutics Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global ADHD Therapeutics Market Segment Percentages, by Type, 2021 (%)
Stimulants
Non-stimulants
Global ADHD Therapeutics Market, by Sale Channel, 2017-2022, 2023-2028 ($ millions)
Global ADHD Therapeutics Market Segment Percentages, by Sale Channel, 2021 (%)
Specialty Clinics
Hospital Pharmacies
Retail Pharmacies
E-Commerce
Global ADHD Therapeutics Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global ADHD Therapeutics Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies ADHD Therapeutics revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies ADHD Therapeutics revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Eli Lilly
Novartis
Takeda
Pfizer
GlaxoSmithKline
Mallinckrodt Pharmaceuticals
Hisamitsu Pharmaceutical
Impax Laboratories
Johnson & Johnson
UCB S.A.
Purdue Parma
Speak to our Custom Research Team and get the Custom Research in a budget
Custom ResearchFrequently Asked Questions ?
A license granted to one user. Rules or conditions might be applied for e.g. the use of electric files (PDFs) or printings, depending on product.
A license granted to multiple users.
A license granted to a single business site/establishment.
A license granted to all employees within organisation access to the product.
Upto Working 24 to 48 hrs
Upto 72 hrs max - Weekends and Public Holidays
Online Payments with PayPal and CCavenue
Wire Transfer/Bank Transfer
Hard Copy
Industry Market SizeSWOT AnalysisIndustry Major PlayersRevenue ForecastsHistorical and Forecast GrowthProfitability Analysis
